Open AccessHigh efficacy of interferon‐free therapy for acute hepatitis C in HIV‐positive patients
Author(s) -
Chromy David,
Mandorfer Mattias,
Bucsics Theresa,
Schwabl Philipp,
Scheiner Bernhard,
Schmidbauer Caroline,
Aichelburg MC,
Ferenci Peter,
Trauner Michael,
Peck-Radosavljevic Markus,
Reiberger Thomas
Publication year - 2019
Publication title -
ueg journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.667
H-Index - 35
eISSN - 2050-6414
pISSN - 2050-6406
DOI - 10.1177/2050640619835394
Subject(s) - ombitasvir , paritaprevir , dasabuvir , medicine , ledipasvir , ritonavir , sofosbuvir , daclatasvir , hepatitis c , gastroenterology , hepatitis c virus , virology , viral load , ribavirin , human immunodeficiency virus (hiv) , virus , antiretroviral therapy
Background The treatment of acute hepatitis C (AHC) with direct‐acting antiviral agents (DAAs) is considered a cornerstone of hepatitis C virus (HCV) elimination strategies, especially in human immunodeficiency virus (HIV)‐infected individuals at high risk of onward transmission. Objective Optimal treatment regimens and duration for AHC in HIV‐coinfected patients remain to be established. Thus, we aimed to evaluate the efficacy and safety of DAA treatment regimens in the setting of AHC. Methods All HIV‐positive patients with a diagnosis of AHC according to the European AIDS Treatment Network (NEAT) consensus attending our clinic after 2014 were included. DAA treatment regimens and duration were based on current recommendations for chronic hepatitis C (CHC) at treatment initiation. Results Thirty‐eight HIV/AHC patients (median age 42.0 years), mostly men who have sex with men (92%), were started on interferon‐free regimens. HCV‐genotype (GT) was predominately GT‐1a (65%). The following DAA regimens were prescribed: ombitasvir/paritaprevir/ritonavir/dasabuvir (42%; 16/38), glecaprevir/pibrentasvir (29%; 11/38), sofosbuvir/ledipasvir (13%; 5/38), ombitasvir/paritaprevir/ritonavir (5%; 2/38), grazoprevir/elbasvir (5%; 2/38) and sofosbuvir/velpatasvir (5%; 2/38). All HIV/AHC patients achieved sustained virologic response 12 weeks after end of treatment (SVR12) (100%; 38/38). DAA‐related adverse events were rare. Conclusion Interferon‐free DAA regimens (including 34% pan‐genotypic regimens) yielded 100% SVR12 in HIV/AHC individuals if treatment durations similar to CHC are applied.